Eliem Therapeutics (ELYM) Competitors $1.63 +0.02 (+1.24%) As of 08/13/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ELYM vs. TRDA, EPRX, IPHA, NLTX, VTYX, ENGN, EDIT, VYGR, GNFT, and SXTCShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Entrada Therapeutics (TRDA), Eupraxia Pharmaceuticals (EPRX), Innate Pharma (IPHA), Neoleukin Therapeutics (NLTX), Ventyx Biosciences (VTYX), enGene (ENGN), Editas Medicine (EDIT), Voyager Therapeutics (VYGR), GENFIT (GNFT), and China SXT Pharmaceuticals (SXTC). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Its Competitors Entrada Therapeutics Eupraxia Pharmaceuticals Innate Pharma Neoleukin Therapeutics Ventyx Biosciences enGene Editas Medicine Voyager Therapeutics GENFIT China SXT Pharmaceuticals Eliem Therapeutics (NASDAQ:ELYM) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability. Which has higher earnings & valuation, ELYM or TRDA? Entrada Therapeutics has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Entrada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEliem TherapeuticsN/AN/A-$35.12M-$0.53-3.08Entrada Therapeutics$210.78M0.95$65.63M-$1.78-2.95 Which has more volatility & risk, ELYM or TRDA? Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the S&P 500. Do insiders & institutionals believe in ELYM or TRDA? 69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 8.1% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is ELYM or TRDA more profitable? Eliem Therapeutics has a net margin of 0.00% compared to Entrada Therapeutics' net margin of -92.30%. Entrada Therapeutics' return on equity of -17.81% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eliem TherapeuticsN/A -47.03% -45.97% Entrada Therapeutics -92.30%-17.81%-14.55% Do analysts prefer ELYM or TRDA? Entrada Therapeutics has a consensus price target of $25.67, indicating a potential upside of 388.89%. Given Entrada Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Entrada Therapeutics is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Does the media prefer ELYM or TRDA? In the previous week, Entrada Therapeutics had 19 more articles in the media than Eliem Therapeutics. MarketBeat recorded 19 mentions for Entrada Therapeutics and 0 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.00 beat Entrada Therapeutics' score of -0.34 indicating that Eliem Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Eliem Therapeutics Neutral Entrada Therapeutics Neutral SummaryEntrada Therapeutics beats Eliem Therapeutics on 13 of the 16 factors compared between the two stocks. Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$48.50M$791.77M$5.61B$9.84BDividend YieldN/A4.84%4.61%4.07%P/E Ratio-3.081.1830.2725.74Price / SalesN/A26.06469.95115.79Price / CashN/A19.5638.2159.48Price / Book0.426.588.846.15Net Income-$35.12M-$4.98M$3.25B$265.06M7 Day Performance-4.12%1.90%3.71%2.60%1 Month Performance14.79%0.50%5.85%2.83%1 Year Performance-73.23%16.35%30.25%25.58% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$1.63+1.2%N/A-72.9%$48.50MN/A-3.089Gap UpTRDAEntrada Therapeutics2.6745 of 5 stars$5.08+1.1%$25.67+405.7%-66.8%$192.98M$210.78M-2.85110EPRXEupraxia Pharmaceuticals1.9757 of 5 stars$5.37+0.7%$11.00+105.0%+102.3%$192.93MN/A-7.0629Positive NewsEarnings ReportIPHAInnate Pharma2.2458 of 5 stars$2.09-3.5%$11.00+427.6%-0.5%$192.20M$21.77M0.00220Short Interest ↑Gap UpNLTXNeoleukin TherapeuticsN/A$20.35-4.1%N/A-38.2%$191.25MN/A-6.5490News CoverageHigh Trading VolumeVTYXVentyx Biosciences2.6506 of 5 stars$2.68+1.3%$7.50+180.4%+57.1%$190.75MN/A-1.5930ENGNenGene3.3552 of 5 stars$3.73+0.9%$23.29+525.1%-33.8%$190.35MN/A-2.2631Short Interest ↓EDITEditas Medicine4.3145 of 5 stars$2.26+2.5%$4.70+108.4%-20.9%$188.77M$32.31M-0.74230Earnings ReportAnalyst ForecastGap DownVYGRVoyager Therapeutics3.7167 of 5 stars$3.35+8.7%$13.25+295.8%-42.5%$185.55M$80M-1.81100GNFTGENFIT2.1616 of 5 stars$3.69-1.2%$13.00+252.8%+3.0%$184.25M$76.77M0.00120SXTCChina SXT Pharmaceuticals0.4031 of 5 stars$1.58-0.3%N/A-80.8%$183.33M$1.74M0.0090Short Interest ↑ Related Companies and Tools Related Companies Entrada Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Innate Pharma Alternatives Neoleukin Therapeutics Alternatives Ventyx Biosciences Alternatives enGene Alternatives Editas Medicine Alternatives Voyager Therapeutics Alternatives GENFIT Alternatives China SXT Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELYM) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access